http://www.insidercow.com/history/company.jsp?company=INCY&B1=SEARCH
Recent INCY News
- Incyte présentera les données de son portefeuille d'oncologie lors de la réunion annuelle 2024 de l'ASCO et du congrès EHA2024 • Business Wire • 05/15/2024 03:44:00 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 05/15/2024 03:10:29 PM
- Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress • Business Wire • 05/14/2024 09:00:00 PM
- Producer Price Inflation Data May Weigh On Wall Street • IH Market News • 05/14/2024 01:05:30 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/13/2024 10:06:33 PM
- Dow Snaps Eight-Day Winning Streak After Lackluster Session • IH Market News • 05/13/2024 08:34:54 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 05/13/2024 03:19:07 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 05/13/2024 11:19:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:18:34 AM
- Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock • Business Wire • 05/13/2024 11:00:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/09/2024 10:40:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 10:25:46 PM
- Incyte to Present at Upcoming Investor Conference • Business Wire • 05/02/2024 12:00:00 PM
- Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs • Business Wire • 04/30/2024 11:00:00 AM
- Incyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorie • Business Wire • 04/23/2024 10:11:00 PM
- Incyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekannt • Business Wire • 04/23/2024 10:01:00 PM
- Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists • Business Wire • 04/23/2024 11:00:00 AM
- Incyte to Report First Quarter Financial Results • Business Wire • 04/11/2024 12:00:00 PM
- Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia • Business Wire • 04/01/2024 12:30:00 PM
- Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/29/2024 08:30:00 PM
- Incyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modérée • Business Wire • 03/11/2024 12:57:00 PM
- Incyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekannt • Business Wire • 03/11/2024 12:57:00 PM
- Incyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaire • Business Wire • 03/11/2024 10:06:00 AM
- Incyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vor • Business Wire • 03/11/2024 09:53:00 AM
- Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis • Business Wire • 03/10/2024 08:05:00 PM
FEATURED Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM
Branded Legacy Inc. Invites Shareholders to Celebrate Milestones at Open House: Announces Share Buyback and Commitment to Authorized Share Count • BLEG • May 15, 2024 8:30 AM
Alliance Creative Group (ACGX) Releases Q1 2024 Financial and Disclosure Report with an 88% increase in Net Income from Q1 2023 to Q1 2024 • ACGX • May 15, 2024 8:30 AM
Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector • CATV • May 15, 2024 8:00 AM
POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • POET • May 14, 2024 10:09 AM